Psyence Biomed
Psyence Biomedical Ltd. (NASDAQ:PBM) is a Nasdaq-listed company with its subsidiary, The Texas Ibogaine Research Corporation, headquartered in Texas. It is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in Neuroplastogens-based therapeutics, the manufacture of pharmaceutical-grade drug candidates and conducting Clinical Trials. The Company is dedicated to addressing unmet mental health needs and is committed to an evidence-based approach to developing safe, effective and FDA-approved nature-derived Neuroplastogens treatments across a range of mental health disorders.
Psyence Biomed
The world’s first life science biotechnology company traded on the Nasdaq (NASDAQ:PBM) focused on the development of botanical (nature derived, or non-synthetic) psilocybin-based psychedelic medicines. The name “Psyence” combines the words “psychedelics” and “science” to affirm Psyence Biomed’s commitment to an evidence-based approach to innovation as it works to develop safe and effective, nature-derived psychedelic therapeutics to treat a broad range of mental health disorders. Psyence Biomed is initially focused on mental health disorders in the context of Palliative Care.
Our
Mission
Pioneering the use of natural
psychedelics for mental health
We are a life science biotechnology company developing innovative, safe and effective psychedelic and nature-centred solutions for mental health.
Our key focus area is palliative care. In particular, Psyence is targeting the indications of anxiety and depression, and associated ailments, within the context of palliative care.
Leading the Business of Medicine and Science
Working at the intersection of medicine, commerce, and science, our physician-led company is headed by an experienced entrepreneur Jody Aufrichtig (CEO) with Dr. Neil Maresky, a physician, as Global Head of Clinical Development. Dr Maresky has over 3 decades of experience in launching 50 NCE’s. Our expertise in intellectual property, capital markets and business development brings a global track record of sustainable growth and shareholder value.
Leading the Business of Medicine and Science
Working at the intersection of medicine, commerce, and science, our physician-led company is headed by an experienced entrepreneur Jody Aufrichtig (CEO) with Dr. Neil Maresky, a physician, as Global Head of Clinical Development. Dr Maresky has over 3 decades of experience in launching 50 NCE’s. Our expertise in intellectual property, capital markets and business development brings a global track record of sustainable growth and shareholder value.
Our News
We believe in keeping our stakeholders informed and engaged with clear and timely communication. Whether it’s news about our scientific breakthroughs, regulatory updates, or leadership commentary, this is your trusted source for all formal communications from Psyence Biomed.
Our News
Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment
Psyence BioMed will host an exclusive investor and shareholder webinar on September 16, 2025, at 12:00 PM EST, featuring members of its Scientific Advisory Board. The session will highlight the Company’s ongoing clinical development programs and share insights into future strategic initiatives, with expert contributions from Dan Stein, Seth Feuerstein, Albert Garcia-Romeu, and Clive Ward-Able.
Psyence BioMed Webinar For Investors And Shareholders, Featuring Members Of Its Scientific Advisory Board.
Psyence BioMed will host an exclusive investor and shareholder webinar on September 16, 2025, at 12:00 PM EST, featuring members of its Scientific Advisory Board. The session will highlight the Company’s ongoing clinical development programs and share insights into future strategic initiatives, with expert contributions from Dan Stein, Seth Feuerstein, Albert Garcia-Romeu, and Clive Ward-Able.
H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025
Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that it will present at the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8–10, 2025.